Login (DCU Staff Only)
Login (DCU Staff Only)

DORAS | DCU Research Repository

Explore open access research and scholarly works from DCU

Advanced Search

Challenges of drug resistance in the management of pancreatic cancer

Sheikh, Rizwan, Walsh, Naomi orcid logoORCID: 0000-0002-2178-3564, Clynes, Martin orcid logoORCID: 0000-0002-3093-8185, O'Connor, Robert orcid logoORCID: 0000-0001-5794-6188 and McDermott, Ray (2014) Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 10 (10). pp. 1647-1661. ISSN 1473-7140

Abstract
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor). Only 25-30% of patients respond to this treatment and patients who do respond initially ultimately exhibit disease progression. Median survival for pancreatic cancer patients has reached a plateau due to inherent and acquired resistance to these agents. Key molecular factors implicated in this resistance include: deficiencies in drug uptake, alteration of drug targets, activations of DNA repair pathways, resistance to apoptosis, and the contribution of the tumor microenvironment. Moreover, for newer agents including tyrosine kinase inhibitors, over expression of signaling proteins, mutations in kinase domains, activation of alternative pathways, mutations of genes downstream of the target, and/or amplification of the target represent key challenges for treatment efficacy. Here we will review the contribution of known mechanisms and markers of resistance to key pancreatic cancer drug treatments.
Metadata
Item Type:Article (Published)
Refereed:Yes
Uncontrolled Keywords:Pancreatic cancer; Drug resistance; anticancer therapy; Capecitabine; Gemcitabine; Erlotinib; Tyrosine Kinase Inhibitor
Subjects:Medical Sciences > Cancer
DCU Faculties and Centres:DCU Faculties and Schools > Faculty of Science and Health > School of Nursing and Human Sciences
Research Initiatives and Centres > National Institute for Cellular Biotechnology (NICB)
Publisher:Taylor & Francis
Official URL:https://doi.org/10.1586/era.10.148
Copyright Information:© 2014 Taylor & Francis
Use License:This item is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 License. View License
ID Code:16057
Deposited On:11 May 2011 15:40 by Naomi Walsh . Last Modified 28 Nov 2023 12:21
Documents

Full text available as:

[thumbnail of Challanges of drug resistance in the management of pancreatic cancer]
Preview
PDF (Challanges of drug resistance in the management of pancreatic cancer) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
217kB
Downloads

Downloads

Downloads per month over past year

Archive Staff Only: edit this record